Biotech News

SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024

Sophia Genetics (SOPH)Sophia GeneticsEarnings

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.

The call will be webcast live on the SOPHiA GENETICS Investor Relations website . Additionally, a replay will be available on the website after its completion.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products, and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram . Where others see data, we see answers.

Related news

Sophia Genetics

Sophia Genetics is a healthcare technology company focused on data-driven diagnostics and clinical decision support. Its business is centered on applying software to genomic and pathology workflows.

Recent company news

Stock data

Close
8.65 USD
Market cap
354.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States